Vinorelbine
Tubulin Inhibitor
DB00361
Approved Indication
For the treatment of non-small-cell lung carcinoma.
1
Targets
0
Resistance Mutations
1
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
The antitumor activity of vinorelbine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Vinorelbine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Like other vinca alkaloids, vinorelbine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca<sup>2+</sup>-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis.
Details
DrugBank ID
DB00361 ↗
Approval Date
2003-03-01
Molecular Weight
778.9323 g/mol
Drug Class
Tubulin Inhibitor
ATC Codes
L01CA04
Synonyms
5'-Noranhydrovinblastine, Nor-5'-anhydrovinblastine, Vinorelbin
PubChem
CID: 44424639 ↗
ChEMBL
CHEMBL607994 ↗
SMILES
[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@@](CC)([C@@H](OC(C)=O)[C@@]2(O)C(=O)OC)[C@@]13[H])[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
ADMET Profile
Computing properties…
Drug References (DrugBank)